Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599477 | 0.91 | CA2 (0.45) | PPARGFFAR1PTPN1RXRARXRB | |
| SCHEMBL3594379 | 0.87 | PPARG (0.48) | PPARGFFAR1PTPN1PPARAALDH1A1 | |
| SCHEMBL2571571 | 0.85 | FFAR1 (0.43) | PPARGFFAR1PTPN1PPARAALDH1A1 | |
| SCHEMBL3587126 | 0.85 | HRH3 (0.41) | PPARGFFAR1PTPN1PPARAALDH1A1 | |
| SCHEMBL3589923 | 0.84 | ALDH1A1 (0.56) | PPARGFFAR1PTPN1PPARAALDH1A1 | |
| SCHEMBL2569823 | 0.84 | FFAR1 (0.45) | PPARGFFAR1PTPN1PPARAMAPT | |
| SCHEMBL3591037 | 0.83 | PTPN1 (0.62) | PPARGFFAR1PTPN1PPARAALDH1A1 | |
| SCHEMBL525525 | 0.82 | PPARG (0.59) | PPARGFFAR1RXRAPPARAALDH1A1 | |
| SCHEMBL1384582 | 0.81 | PTPN1 (0.43) | PPARGFFAR1PTPN1ALDH1A1NPSR1 | |
| SCHEMBL3583787 | 0.81 | PPARG (0.58) | PPARGFFAR1RXRAPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004185-B1 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | claimed |
| US-7781464-B2 | Heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-2004185-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | Bexel Pharmaceuticals Inc (US) | 2008-12-24 | — | — | EP | claimed |
| WO-2007097992-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | claimed |
| EP-2004185-B1 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-7781464-B2 | Heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2004185-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | Bexel Pharmaceuticals Inc (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007097992-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | FFAR4, FFAR3, GPR119 | PPARG 12/4885FFAR1 5/4885PTPN1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.